Success Metrics

Clinical Success Rate
76.0%

Based on 57 completed trials

Completion Rate
76%(57/75)
Active Trials
6(6%)
Results Posted
39%(22 trials)
Terminated
18(19%)

Phase Distribution

Ph phase_1
3
3%
Ph not_applicable
16
17%
Ph early_phase_1
1
1%
Ph phase_2
12
13%
Ph phase_4
31
33%
Ph phase_3
25
27%

Phase Distribution

4

Early Stage

12

Mid Stage

56

Late Stage

Phase Distribution88 total trials
Early Phase 1First-in-human
1(1.1%)
Phase 1Safety & dosage
3(3.4%)
Phase 2Efficacy & side effects
12(13.6%)
Phase 3Large-scale testing
25(28.4%)
Phase 4Post-market surveillance
31(35.2%)
N/ANon-phased studies
16(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

57 of 79 finished

Non-Completion Rate

27.8%

22 ended early

Currently Active

6

trials recruiting

Total Trials

93

all time

Status Distribution
Active(8)
Completed(57)
Terminated(22)
Other(6)

Detailed Status

Completed57
Terminated18
unknown6
Withdrawn4
Recruiting4
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
93
Active
6
Success Rate
76.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.1%)
Phase 13 (3.4%)
Phase 212 (13.6%)
Phase 325 (28.4%)
Phase 431 (35.2%)
N/A16 (18.2%)

Trials by Status

active_not_recruiting22%
unknown66%
withdrawn44%
not_yet_recruiting22%
recruiting44%
completed5761%
terminated1819%

Recent Activity

Clinical Trials (93)

Showing 20 of 93 trialsScroll for more
NCT07109245Phase 4

Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?

Recruiting
NCT03021486Phase 2

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

Active Not Recruiting
NCT03743649Phase 2

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Active Not Recruiting
NCT07246187Phase 3

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

Recruiting
NCT05431595Phase 2

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Recruiting
NCT02098499Phase 4

Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT

Withdrawn
NCT07087925Not Applicable

Comparison of Haloperidol and Ondansetron in Reducing Postoperative Nausea and Vomiting in RA-SAB Patients

Completed
NCT04002700

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Completed
NCT06993194Not Applicable

Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury

Not Yet Recruiting
NCT05065567Phase 3

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Terminated
NCT02431702Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Completed
NCT00156104Phase 3

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Completed
NCT06395428Phase 4

Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department

Recruiting
NCT06428084Phase 2

Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV

Completed
NCT06370442Phase 3

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

Not Yet Recruiting
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT04715230Phase 2

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Terminated
NCT05690698Phase 3

Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium

Completed
NCT04764344Phase 4

Haloperidol for the Treatment of Nausea and Vomiting in the ED

Completed
NCT05803642Phase 3

A Study of Olanzapine in Patients With Acute Agitation

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
93